Phase II study of high dose weekly intravenous human lymphoblastoid interferon in renal cell carcinoma. A study of the National Cancer Institute of Canada Clinical Trials Group.
D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007370:Interferon Type I / Q000008:administration & dosage* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D007370:Interferon Type I